Does Ozempic Slow Your Metabolism? What the Measurements Show

Ozempic does not slow your metabolism beyond what losing the weight does. Your body burns fewer calories as it gets smaller, on semaglutide or on any diet, and the studies that measured it found that drop to be about what the lost weight predicts. In the one study that compared it with dieting alone, the extra slowdown was no bigger on semaglutide than in people dieting without it.^[8] Tirzepatide, the drug in Mounjaro and Zepbound, showed the same pattern in a calorimetry chamber.^[5] The drugs work by cutting how much you eat, not by changing how much energy you burn. The studies are small, and nobody has yet measured metabolism after people stop.

What the labels say about metabolism

Nothing, directly. The Ozempic label says semaglutide lowers blood glucose and reduces body weight; the word “appetite” does not appear in it, and neither does energy expenditure.^[1] The obesity labels are more specific about how the weight comes off. Wegovy’s says semaglutide decreases calorie intake and that the effect is likely mediated through appetite.^[2] Zepbound’s says the same of tirzepatide, word for word.^[3] Both add that the drug lowers weight with more fat lost than lean tissue.

Neither label claims the drug speeds metabolism up or slows it down. That matches the trials. The measured mechanism is eating less.

Why metabolism drops when weight drops

Resting metabolic rate measures the calories spent keeping you alive while you lie still, and it scales with the size of the body, mostly with its lean tissue. Lose 15 kilograms and there is less tissue to run, so the number falls. That part is arithmetic, and it happens with any method of weight loss.

The contested part is whether it falls further than the smaller body explains. That extra drop is called adaptive thermogenesis or metabolic adaptation. The classic study held people at 10% or more below their usual weight and found total daily energy expenditure ran 6 to 8 kcal lower per kilogram of fat-free mass than before, with resting and non-resting burn each down 3 to 4 kcal per kilogram.^[12] Because those figures are already scaled to fat-free mass, the drop was not just the result of losing muscle. It was the body economizing.

How large and how lasting that economizing is depends on when it is measured. Six years after The Biggest Loser, 14 contestants were still burning about 499 kcal a day less at rest than their body composition predicted, even after regaining most of the weight.^[13] Those were extreme losses driven by extreme exercise and restriction. Studies that measure people once their weight has stopped moving find much less. In 71 adults put on a 1,000-calorie-a-day diet for eight weeks, the extra slowdown was 92 kcal a day during active weight loss and roughly halved once weight stabilized.^[14] In 171 women followed for two years, it was 54 kcal a day after weight loss and statistically undetectable at one and two years, and it did not predict who regained.^[15]

So the honest baseline is this: metabolism falls with weight loss, a modest extra slowdown is common while you are actively losing, and how much of it persists is still argued over. The question for the drugs is whether they make any of that worse.

What happened when semaglutide was measured

Four sets of semaglutide measurements exist, and they point the same way.

The cleanest of these is the oldest. In a 12-week randomized crossover, the same 30 people took semaglutide and placebo in turn. On semaglutide they ate 24% less across a day of unlimited meals and lost 5.0 kg, mostly fat. Corrected for lean body mass, their resting burn matched what it was on placebo.^[4]

The longer studies are less controlled but more realistic. In SEMALEAN, a French study of people with severe obesity on Wegovy’s 2.4 mg dose, resting burn fell 244 kcal a day over the first seven months while weight came down about 10%. It then climbed back 140 kcal a day by month 12, and per kilogram of lean tissue it ended higher than at month seven.^[7] There was no comparison group, so that rebound cannot be credited to the drug.

The Barcelona study supplies the comparison. Over 12 months, people on semaglutide lost 11 kg more than those in a lifestyle program alone. Resting energy expenditure fell in both groups, and part of the fall exceeded what changes in fat, lean mass, age and sex predicted. But that extra slowdown was no larger on semaglutide: about 210 kcal a day, against about 373 in the lifestyle group. The gap between them was not statistically significant.^[8] It was an observational study of routine clinic records, not a trial. It is still the most direct answer to the question people ask.

A 2026 scoping review of every human study it could find on GLP‑1 drugs and energy expenditure concluded that the drugs on their own do not appear to change energy expenditure independent of weight loss.^[6] It also flagged the limits. Most studies measured only resting metabolic rate, four used a whole-room calorimetry chamber, none used doubly labeled water (the method for measuring free-living daily burn), and almost half were inconclusive because of how they were analyzed.^[6]

Does Mounjaro slow metabolism?

Tirzepatide has the best-measured study of the group. In a phase 1 trial at Pennington Biomedical, people with obesity spent two days in a sealed metabolic chamber before and after 18 weeks of tirzepatide 15 mg or placebo, with both groups on a diet.^[5][6]

Daily burn fell more on tirzepatide, by about 440 kcal against about 200 on placebo. Tirzepatide users had also lost much more tissue. Once the analysis adjusted for the change in body composition, there was no difference between the groups in total, resting or sleeping energy expenditure.^[6] The authors put the conclusion in their title: tirzepatide did not impact metabolic adaptation in people.^[5] What it did do was shift fuel use toward fat. The full story of that trial, including the mouse result that did not carry over, is in the tirzepatide metabolic adaptation study.

Two caveats belong next to that result. The trial was small and short, so a modest effect could have been missed. And several authors work for Eli Lilly, which makes tirzepatide; a null result about their own drug is not the finding a sponsor would choose.

What the older drug, liraglutide, showed

Liraglutide (Saxenda, Victoza) has been studied longest, and the results scatter around zero. A 2018 meta-analysis of ten trials and 282 people judged its effect on resting energy expenditure, and that of exenatide, to be neutral.^[9] A 26-week randomized trial in type 2 diabetes found resting burn about 52 kcal a day lower on liraglutide and 44 higher on placebo, a between-group difference that just missed statistical significance; the authors concluded the weight loss came from eating less.^[10] A small six-month study in 11 people found no change in 24-hour energy expenditure despite a 10.5 kg loss.^[11] None suggests the drug slows metabolism by itself, and none is large.

The muscle question

The usual argument for “Ozempic wrecks your metabolism” runs through muscle: the drug strips lean tissue, lean tissue burns calories, so metabolism falls. The first two steps are partly true and the conclusion does not follow.

In SURMOUNT-1’s scanning substudy, tirzepatide users shed roughly three parts fat to one part lean mass, and the placebo group lost weight in the same ratio.^[16] A 2026 meta-analysis of 20 randomized trials put the lean share at 35.2% for semaglutide, 25.4% for tirzepatide and 26.2% for lifestyle programs, with no significant difference between the drugs as a group and dieting.^[17] Lean mass also includes water and organs, not only muscle. Adding resistance training brought the lean share down to 17.5%.^[17]

Losing lean tissue does lower resting burn, and that is already counted in the calorimetry studies above, which adjust for it. After the adjustment, the drugs showed no extra slowdown. The detail on what the scans measure and what they cannot tell you about strength is in lean mass on a drug versus dieting and GLP‑1 hair loss and muscle loss.

Why weight loss stalls on Ozempic

A plateau feels like a metabolism that has shut down. The energy-balance arithmetic explains it without that. A modeling study of long-term GLP‑1 treatment, using a published model of human metabolism, estimated that energy expenditure fell about 9% from baseline by week 98 and then held steady, while intake, cut sharply at first, crept back up until it matched the lower burn.^[18] Where the two lines meet, weight stops falling. That paper is a simulation, not a measurement, and its lead author works for a commercial weight-loss company.

The trial definitions of a plateau, and why many people counted as plateaued were still losing, are covered in what a plateau actually means.

Does it speed metabolism up instead?

Some coverage has claimed the opposite. It traces to a 30-person Irish study in people with sleep apnea, where a GLP‑1 regimen raised the uptake of a glucose tracer in belly fat on PET scans.^[19] That is a measure of tissue activity on an imaging scan, not of calories burned, and the authors described it as a hypothesis worth further study. The calorimetry studies above, which measure calories directly, have not found a rise in energy expenditure on GLP‑1 drugs alone.^[6]

Is metabolism slower after stopping Ozempic?

No published study has measured energy expenditure in people after they stopped semaglutide or tirzepatide. What can be said comes from the weight-loss research in general. A body that stays lighter burns less, so if you keep some of the weight off, your daily burn stays correspondingly lower. Whether any extra slowdown lingers is the disputed part: it persisted for years in the Biggest Loser contestants^[13] and largely faded under weight stability in the larger diet studies.^[14][15]

Regain after stopping is driven mostly from the other side of the ledger. Appetite returns as the drug clears, and intake rises to meet and pass the lower burn. The trial data on how fast that happens are in stopping Ozempic or Wegovy and stopping tirzepatide. The first randomized trial of tapering semaglutide, REST, has published only its protocol, and its listed outcomes are weight, blood pressure and the hunger hormone ghrelin rather than metabolic rate.^[20]

What the evidence supports doing

• Expect a lower calorie burn as weight comes off. It is the size of the body, not damage from the drug, and it is the same on a diet.
• Lift something. Resistance training was the one intervention that cut the lean share of weight lost, to 17.5% from about a quarter.^[17] The meta-analysis authors also named adequate protein; the protein calculator gives a target.
• Read a stall as energy balance, not a broken metabolism. Intake catching up with a smaller body’s needs is the expected shape of the curve.^[18]